TY - T1的血管紧张素转换酶2和血管紧张素(1 - 7)轴在肺动脉高血压JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02416 -2019欧元SP - 1902416 AU胡里奥·桑多瓦尔盟-莱昂纳多Del Valle-Mondragon盟-费利佩•美索盟Nayeli Zayas AU -托马斯Pulido盟里卡多Teijeiro AU -赫Gonzalez-Pacheco盟然而Olmedo-Ocampo AU -卡洛斯Sisniega盟婀瑞思利Paez-Arenas盟Gustavo Pastelin-Hernandez AU -穆Gomez-Arroyo盟诺伯特·f·Voelkel Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/early/2020/03/26/13993003.02416 2019. -抽象N2 -背景在肺动脉高血压动物模型(PAH),血管紧张素转换酶2型(ACE2)和血管紧张素1 - 7 (Ang -(1 - 7))已被证明有常,anti-proliferative anti-fibrotic和anti-hypertrophic属性。然而,ACE2-Ang的地位和作用——人类PAH(1 - 7)轴是不完全理解。方法:我们对85名患者的诊断多环芳烃的截然不同的病因。55健康献血者的年龄和性别配对担任控制。血样经肺动脉在PAH患者右心catheterisation。对两组外周血得到。Ang -(1 - 7)和血管紧张素ⅱ(AngII)是衡量区域毛细管电泳。醛固酮,血管紧张素-(1 - 9),血管紧张素,用ELISA检测(Ang-A)和ACE2,决心保持酶和ACE2活动。47岁的85名患者的结果特发性PAH, 25 PAH-associated有先天性心脏病,13有PAH-associated胶原血管疾病。控制相比,患者多环芳烃浓度较高AngII[(1.03(差0.72 - -1.88)和0.19 (IQR 0.10 - -0.37) pmoles·毫升−1;术中;0.001)]和醛固酮[(88.7(58.7 -132)和12.9 (9.55 - -19.9)ng·dL−1;术中;0.001)]。相反,PAH患者Ang -(1 - 7)的浓度低于控制[(0.69(0.474 - -0.91)和4.07 (2.82 - -6.73)pmoles·毫升−1;术中;0.001)],和低浓度Ang -(1 - 9),和Ang-A。 Similarly, the ACE2 concentration was higher than in controls [(8.7(5.35–13.2) versus 4.53(1.47–14.3)ng·mL−1;p=0.011)], whereas the ACE2 activity was significantly reduced [(1.88(1.08–2.81) versus 5.97(3.1–17.8)nmoles·mL−1;p<0.001)]. No significant differences were found among the three different etiologic forms of PAH.Conclusions The AngII-ACE2-Ang- (1–7) axis appears to be altered in human PAH and we propose that this imbalance, in favour of AngII, plays a role in the pathogenesis of the severe PAH. Further mechanistic studies are warranted.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. SANDOVAL has nothing to disclose.Conflict of interest: Dr. Del Valle-Mondragon has nothing to disclose.Conflict of interest: Dr. Masso has nothing to disclose.Conflict of interest: Dr. Zayas has nothing to disclose.Conflict of interest: Dr. Pulido reports grants from Actelion, personal fees from Actelion, personal fees from Actelion, grants from Bayer, personal fees from Bayer, personal fees from Bayer, grants from Lilly, personal fees from Pfizer, grants from Reata Pharmaceuticals, personal fees from Akros Pharma, grants from United Therapeutics, outside the submitted work; .Conflict of interest: Dr. Teijeiro Paradis reports grants from CONACYT , during the conduct of the study; .Conflict of interest: Dr. González-Pacheco has nothing to disclose.Conflict of interest: Dr. Olmedo- Ocampo has nothing to disclose.Conflict of interest: Dr. Sisniega has nothing to disclose.Conflict of interest: Dr. Paez-Arenas has nothing to disclose.Conflict of interest: Dr. Pastelin has nothing to disclose.Conflict of interest: Dr. Gómez-Arroyo has nothing to disclose.Conflict of interest: Dr. Voelkel has nothing to disclose. ER -